Parallax Volatility Advisers
TVTX icon

Parallax Volatility Advisers’s Travere Therapeutics TVTX Stock Holding History

Parallax Volatility Advisers’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-67,000
Closed -$1.37M – 3182
2020
Q2 		$1.37M Buy
+67,000
New +$1.07M ﹤0.01% 1616
2019
Q4 		– Sell
-45,000
Closed -$522K – 2653
2019
Q3 		$522K Buy
+45,000
New +$744K ﹤0.01% 1592

Other funds holding TVTX

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Parallax Volatility Advisers's TVTX Position: Q4 2023 in Review

Parallax Volatility Advisers sold out of Travere Therapeutics (TVTX) in Q4 2023, closing a stake of 24,112 shares — an estimated $216K sold.

Parallax Volatility Advisers first reported a position in TVTX in Q4 2017 and held it in 5 quarters. The position peaked at $408K in Q2 2020. 165 funds tracked by Wall St. Rank hold TVTX as of Q4 2023.

  • Parallax Volatility Advisers reported no remaining Travere Therapeutics position as of Q4 2023 after selling out during the quarter.
  • Parallax Volatility Advisers sold 24,112 Travere Therapeutics shares in Q4 2023, an estimated $216K.
  • Parallax Volatility Advisers first reported a position in Travere Therapeutics in Q4 2017 and held it in 5 quarters.
  • Parallax Volatility Advisers's Travere Therapeutics position peaked at $408K in Q2 2020.
  • 165 funds tracked by Wall St. Rank held Travere Therapeutics as of Q4 2023.

Based on Parallax Volatility Advisers's 13F filing for Q4 2023, filed 14 Feb 2024.